Search

Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (propiolactone inactivated)

This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

ALT-2074

An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. … BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.

Tavaborole

Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).

LNP-nCoVsaRNA Vaccine

The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation.

Antimony potassium tartrate

It has irritant emetic properties and may cause lethal cardiac toxicity among other adverse effects.

Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen

grown in another culture. … Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

NOX-100

NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body.

Surotomycin

It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. … Surotomycin has a fourfold greater in vitro potency than vancomycin against C.

4-nitrophenyl-beta-D-galactoside

Calcium sulfate